Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Nephropathy
Conditions
Diabetic Nephropathy, Type 2 Diabetes
Trial Timeline
May 1, 2014 → Dec 1, 2015
NCT ID
NCT02150707About Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1
Dipeptidyl-Peptidase IV Inhibitors + Glucagon-Like Peptide 1 is a pre-clinical stage product being developed by Eli Lilly for Diabetic Nephropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02150707. Target conditions include Diabetic Nephropathy, Type 2 Diabetes.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Nephropathy were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02150707 | Pre-clinical | Completed |
Competing Products
20 competing products in Diabetic Nephropathy